Project targets Sample Clauses

The Project Targets clause defines the specific objectives, milestones, or deliverables that a project must achieve within a set timeframe. It typically outlines measurable goals such as completion dates, quality standards, or performance metrics, and may specify how progress will be tracked or reported. By clearly establishing these targets, the clause ensures all parties have a shared understanding of expectations, helping to manage performance and reduce disputes over project outcomes.
Project targets please set out here the specific output and outcome targets that have been agreed with the GLA, along with any wider measures that you will be assessing your project performance against.
View SourceView Similar (6)
Project targets. (Section III) will provide detailed information about the estimated number of children, families, and providers to be served through the project, as well as other data. F5CA recognizes some counties may not have all of the data requested at the time the workplan is due. The table presents the data elements that counties will be asked to track and report on over the course of their DLL Expansion projects. The detailed table is provided now, so that counties can develop systems to gather and document the key data elements listed moving forward. Additional Questions (Section IV) requests additional information not fully captured in the original application about planned outreach and identification of populations served. Submit the completed workplan, project targets, and additional questions to the F5CA DLL Pilot team by emailing them to ▇▇▇▇▇▇▇▇@▇▇▇▇▇▇.▇▇.▇▇▇ within 45 days of execution of the LAA. Templates will be available on the DLL Pilot webpage at ▇▇▇▇://▇▇▇▇.▇▇.▇▇▇/partners/investments.html#dll.
View Source
Project targets. (i) If: (A) the City determines that the Company failed to meet a Project Target for a Project Year; and (B) the Project Compliance Percentage for such Project Year is less than 90%, and the City and the Company are unable to resolve any dispute with respect to the Company’s calculation (as contemplated by Subsection 5.1(c)); then the City may deliver to the Company a written request for the Company to deposit with the Escrow Agent (the “Deposit Request”) an amount equal to the following (the “Deposit Amount”): (A) the lesser of: (1) the Project Target Satisfaction Amount; or (2) any amount agreed upon by the City and the Company (the “Adjusted Amount”); in either case, less (B) any Escrow Funds held by the Escrow Agent as a result of any prior Deposit Requests. Subject to Subsection 6.4(c), within 30 days after the date of delivery of the Deposit Request, the Company shall deposit the Deposit Amount with the Escrow Agent, to be held in accordance with Subsection 6.4(e). Notwithstanding anything in this Agreement to the contrary, the Company shall not be obligated to deposit: (A) any amount if the Project Compliance Percentage for a Project Year is at least 90% and any Escrow Funds then on deposit shall be returned to the Company as provided in Subsection 6.4(e)(ii); or (B) any amount in excess of the Deposit Amount for any failure to meet a Project Target in accordance with Subsection 5.1(c), and any Escrow Funds then on deposit in excess of the Deposit Amount shall be returned to the Company as provided in Subsection 6.4(e)(ii). (ii) Notwithstanding the foregoing, the aggregate amount payable to the City pursuant to this Subsection shall not exceed the total amount of the Project Funds. (iii) The remedies provided to the City in Subsection 6.4(b) shall be available against any Company Party that receives any portion of the Project Funds as though such Company Party were: (A) the “Company” hereunder; and (B) were a party hereto; but only to the extent of the portion of the Project Funds received by such Company Party.
View Source
Project targets. To provide intergenerational opportunities with ten schools/youth organisations and ten care homes to reach up to 300 young people across XXX and XXX neighbourhoods as described in the delivery agreement (Annex A).
View Source
Project targets. (i) The Company shall meet, or cause to be met: (A) the Capital Investment Targets; (B) the Employment Target; and (C) the Wage Target; in each case on or before the Project Target Termination Date. If the Company fails to meet one or more of the Project Targets, then: (A) the provisions of Section 6.4 shall apply; and (B) such failure is not, and shall not result in, an Event of Default. (ii) On or before: (A) April 30, 2014; and (B) each April 30 thereafter during the Term; the Company, at its cost, shall provide to the City a report of the Company’s investment during the Project Period; provided that the Company shall be required to provide only one such report after the Capital Investment Target is met. Such report shall: (A) include a calculation of the Capital Investment Compliance Percentage for the applicable Project Year; and (B) include reasonable supporting information so as to substantiate such report. If the City disputes such calculation, then the City shall give written notice of such dispute to the Company within 30 days after the City’s determination. Such written notice shall: (A) detail the basis for such dispute; and (B) if available, include the City’s own calculation of the Capital Investment Compliance Percentage. Representatives of the City and the Company shall meet in person to review and discuss such dispute and related calculation(s) within 30 days after the date of such written notice to the Company. (iii) On or before: (A) April 30, 2014; and (B) each April 30 thereafter during the Term; the Company, at its cost, shall provide to the City a report as to the Company’s employment during the immediately preceding Project Year. Each such report shall: (A) include a calculation of the Employment Compliance Percentage for the applicable Project Year; and (B) reasonable supporting information so as to substantiate such report. If the City disputes such calculation, then the City shall give written notice of such dispute to the Company within 30 days after the City’s determination. Such written notice shall: (A) detail the basis for such dispute; and (B) if available, include the City’s own calculation of the Employment Compliance Percentage. Representatives of the City and the Company shall meet in person to review and discuss such dispute and related calculation(s) within 30 days after the date of such written notice to the Company. (iv) On or before: (A) April 30, 2014; and (B) each April 30 thereafter during the Term; the Company,...
View Source
Project targets. Full integration of the FC energy production system with a renewable energy production: – Increased energy efficiency under stand alone configuration – Durability – 24/7 operation with four digit availability • Benchmarking of different technical configurations for fuel cells integrated with renewable sources: – European FC and H₂ production technologies (Dantherm, MES, GreenHydrogen) toghether with a US product (IdaTech) are benchmarked with a specific application with a wide potential 5÷10 kWp RBS • Tipical Radio Configuration 3x2 WCDMA • N° 3 Radio Unit, N°1 Digital Unit • Tipical power consuption 1000W • Nominal voltage Vdc -48 • Operating voltage range-40.0 to -58.5 Vdc • Operating environment Temperature +5° to +50°C • Operating environment Relative Humidity 5 – 85% • Variation Load • Traffic Load (daily)
View Source
Project targets. 4.2.1 The Apprenticeship Start target for the Early Connect pilot has been set at 150. These targets will be achieved via the light touch and intensive models. 4.2.2 DfE will continue to collect data via the ILR to monitor general apprenticeship trends. It is anticipated that the Early Connect pilot will directly achieve 150 of these starts in the 18+ category through the light touch and intensive support model. 4.2.3 The pilot will also collate information on soft outcomes such as applications submitted, interviews secured, students who are apprenticeship ready and students reporting increased confidence.
View Source

Related to Project targets

  • Development Milestones In addition to its obligations under Paragraph 7.1, LICENSEE specifically commits to achieving (either itself or through the acts of a SUBLICENSEE) the following development milestones in its diligence activities under this AGREEMENT: (a) (b).

  • Project Goals The schedule, budget, physical, technical and other objectives for the Project shall be defined.

  • Targets Seller’s supplier diversity spending target for Work supporting the construction of the Project prior to the Commercial Operation Date is ____ percent (___%) as measured relative to Seller’s total expenditures on construction of the Project prior to the Commercial Operation Date, and;

  • Development Milestone Payments TriSalus shall pay (or cause to be paid) to Dynavax, in accordance with and subject to the terms of this Section 2.3, Section 2.4 and Section 6.4 (each such milestone, a “Development Milestone”, and each payment in respect thereof, a “Development Milestone Payment”): (i) Upon the successful completion by a Milestone Obligor after the Closing of a [**] study with respect to a Product using PEDD, a payment of [**] US Dollars ($[**]), with such Development Milestone Payment being payable only once (for purposes of the foregoing, successful completion means completion of such study in accordance with the plan for such study); (ii) For the first patient Dosed by a Milestone Obligor in each Phase 1 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iii) For the first patient Dosed by a Milestone Obligor in each Phase 2 Clinical Trial for a Product for each Indication, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (iv) For each Phase 2 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 2 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 2 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (v) For each Phase 3 Clinical Trial for a Product for each Indication conducted by or on behalf of a Milestone Obligor meeting the primary endpoint for such Phase 3 Clinical Trial based on full tables, figures and listings or continued development of such Product for the same Indication as such Phase 3 Clinical Trial, a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products are in development by Milestone Obligor; (vi) Upon receipt by a Milestone Obligor of each Regulatory Approval for any Product for any Indication in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (vii) Upon receipt by a Milestone Obligor for each Regulatory Approval of any Product for any Indication in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments, regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; (viii) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vi) for receipt of such Regulatory Approval), regardless of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval; and (ix) Upon receipt by a Milestone Obligor for each Regulatory Approval for a Product with Orphan Drug Exclusivity for each Indication of a Product in any country or region outside the U.S., a payment of [**] US Dollars ($[**]), up to a maximum of [**] such payments (which, for clarity, shall be payable in addition to the Development Milestone payable under Section 2.3(a)(vii) for receipt of such Regulatory Approval), regardless ​ of how many Indications are pursued for a Product or how many Products achieve Regulatory Approval.

  • Milestones Subject to the provisions of the SGIP, the Parties shall agree on milestones for which each Party is responsible and list them in Attachment 4 of this Agreement. A Party’s obligations under this provision may be extended by agreement. If a Party anticipates that it will be unable to meet a milestone for any reason other than a Force Majeure event, it shall immediately notify the other Parties of the reason(s) for not meeting the milestone and: (1) propose the earliest reasonable alternate date by which it can attain this and future milestones, and (2) requesting appropriate amendments to Attachment 4. The Party affected by the failure to meet a milestone shall not unreasonably withhold agreement to such an amendment unless: (1) it will suffer significant uncompensated economic or operational harm from the delay, (2) attainment of the same milestone has previously been delayed, or (3) it has reason to believe that the delay in meeting the milestone is intentional or unwarranted notwithstanding the circumstances explained by the Party proposing the amendment.